{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 49,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/4",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.084,
        "w": 0.304,
        "x": 0.348,
        "y": 0.198
      },
      "kind": "image",
      "text": "IMMIX BIOPHARMA",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de65627e-fd1e-485f-967b-dea24f0d60d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.55
      },
      "kind": "list",
      "text": "NextGen CAR-T Pipeline: Lead cell therapy candidate NXC-201: 58 patients treated best-in-class potential in multiple myeloma and AL amyloidosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d8e9d77-e809-4b15-be1f-65457b06e0bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "list",
      "text": "TSTx Pipeline: Lead TSTx candidate IMX-110 for soft tissue sarcoma and solid tumors combined with anti PD-1 (30 patients treated)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af64c035-06c5-48ce-a9fb-1f57ce275347",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Novel cell therapy and tissue specific therapeutics approaches to oncology and immuno-dysregulated diseases. Powered by N-GENIUS Platform for hematologic malignancies + SMARxT Tissue Specific Platform for solid tumors. Pipeline-in-a-drug potential for both NXC-201 and IMX-110 – registrational studies planned for 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "beefdcb9-d5b0-42a6-8630-4203af2e1de3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Note: NXC-201 is developed by Nexcella, Inc, a 98% owned subsidiary of Immix Biopharma (NASDSAQ:IMMX) as of February 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2800300e-3e27-405a-ad11-502e6f282453",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "IMMIX Biopharma Overview - Personalized Therapies for Oncology and Immunology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82198d10-fe8b-4923-a71b-46b721b36d54",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "c782c61d-73a9-406f-a0bd-432431ac0857",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "Introduction to Immix Biopharma and its focus on oncology and immunology",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}